# US 2024/0197756 A1 · Methods of treatment with neuroactive steroids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197756 A1
- Document ID: US20240197756A1
- Status: Published application
- Kind: A1
- Application number: 18/555,222
- Filed: 2022-04-26
- Published: 2024-06-20
- Earliest claimed: 2021-04-26
- Assignees: Praxis Precision Medicines, Inc.
- Applicants: Praxis Precision Medicines, Inc.
- Inventors: Carlos LOYA; Nicholas DEMARTINIS; Gabriel BELFORT
- Web page: https://patentgrep.com/patent/US20240197756A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to methods of treating depression, pain, a musculoskeletal disorder or a motor disorder such as essential tremor with Compound 1 or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A method of treating major depressive disorder (MDD), motor disorders, and/or musculoskeletal conditions in a patient in need thereof comprising orally administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof to a patient in need thereof, in the evening.

### Claim 2 (depends on 1)

The method of claim 1, wherein the evening is about two hours after the evening meal.

### Claim 3 (depends on 1)

The method of claim 1, wherein the evening is about four hours after the evening meal.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the evening is between about 5 p.m. and about 12 a.m.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the evening is about two hours prior to bedtime.

### Claim 6

A method of reducing at least one side effect associated with administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof to a patient in need thereof, comprising administering Compound 1 in the evening, wherein the at least one side effect reduced is chosen from somnolence, sedation, dizziness, lightheadedness, fatigue, euphoria, feeling drunk, feeling abnormal, headache, cognitive disorder, disturbance of attention, memory impairment, slowed cognition, decreased alertness, constipation, or diarrhea.

### Claim 7 (depends on 6)

The method of claim 6, wherein the at least one side effect associated with the administering of Compound 1 or a pharmaceutically acceptable salt are determined by the guidelines set forth in Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies (2012), described in the ‘NIH-FDA Phase 2 and 3 IND/IDE Clinical Trial Protocol Template’, and reported with standardized terms according to the Medical Dictionary for Regulatory Activities.

### Claim 8

A method of treating a motor disorder in a patient in need thereof comprising orally administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein said administering is in the evening.

### Claim 10 (depends on 9)

The method of claim 9, wherein the evening is about two hours after the evening meal.

### Claim 11 (depends on 9)

The method of claim 9, wherein the evening is about four hours after the evening meal.

### Claim 12 (depends on 9, 10, 11)

The method of any one of claims 9-11, wherein the evening is between about 5 p.m. and about 12 a.m.

### Claim 13 (depends on 9, 10, 11, 12)

The method of any one of claims 9-12, wherein the evening is about two hours prior to bedtime.

### Claim 14 (depends on 8)

The method of claim 8, wherein said administering is during the day.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 8-14, wherein the motor disorder is chosen from cerebellar tremor, intention tremor, dystonic tremor, essential tremor, orthostatic tremor, Parkinsonian tremor, physiological tremor, psychogenic tremor, or rubral tremor.

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 8-15, further comprising co-administering Compound 2:
or a pharmaceutically acceptable salt thereof.

### Claim 17

A method of treating a musculoskeletal condition in a patient in need thereof comprising orally administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said administering is in the evening.

### Claim 19 (depends on 18)

The method of claim 18, wherein the evening is about two hours after the evening meal.

### Claim 20 (depends on 18)

The method of claim 18, wherein the evening is about four hours after the evening meal.

### Claim 21 (depends on 18, 19, 20)

The method of any one of claims 18-20, wherein the evening is between about 5 p.m. and about 12 a.m.

### Claim 22 (depends on 18, 19, 20, 21)

The method of any one of claims 18-21, wherein the evening is about two hours prior to bedtime.

### Claim 23 (depends on 17)

The method of claim 17, wherein said administering is during the day.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 17-23, wherein the musculoskeletal condition is chosen from fibromyalgia, polymyalgia, chronic fatigue syndrome, or systemic exertion intolerance disease.

### Claim 25 (depends on 24)

The method of claim 24, wherein the musculoskeletal condition is fibromyalgia.

### Claim 26

A method of treating essential tremor in a patient in need thereof comprising orally administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein said administering is in the evening.

### Claim 28 (depends on 27)

The method of claim 27, wherein the evening is about two hours after the evening meal.

### Claim 29 (depends on 27)

The method of claim 27, wherein the evening is about four hours after the evening meal.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the evening is between about 5 p.m. and about 12 a.m.

### Claim 31 (depends on 27, 28, 29, 30)

The method of any one of claims 27-30, wherein the evening is about two hours prior to bedtime.

### Claim 32 (depends on 26)

The method of claim 26, wherein said administering is during the day.

### Claim 33 (depends on 26, 27, 28, 29, 30, 31, 32)

The method of any of claims 26-32, further comprising co-administering Compound 2:
or a pharmaceutically acceptable salt thereof.
